English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51496404    線上人數 :  727
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"jia horng kao"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 591-640 / 1180 (共24頁)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-09-04T05:16:59Z Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:58Z A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏 2021-09-04T05:16:58Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:58Z Sarcopenia and chronic liver diseases Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Taiwan consensus statement on the management of chronic hepatitis B Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F.
臺大學術典藏 2021-09-04T05:16:56Z Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B Wei L.; Pavlovic V.; Bansal A.T.; Chen X.; Foster G.R.; He H.; JIA-HORNG KAO; Lampertico P.; Liaw Y.-F.; Motoc A.; Papatheodoridis G.V.; Piratvisuth T.; Plesniak R.; Wat C.
臺大學術典藏 2021-09-04T05:16:56Z Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C.
臺大學術典藏 2021-09-04T05:16:56Z Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:56Z Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction? Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:55Z Large and middle hepatitis B surface antigen: The lower the better? Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:55Z Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏 2021-09-04T05:16:55Z Profile and value of FIB-4 in patients with dual chronic hepatitis C and B Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:54Z Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:54Z Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis Yeo Y.H.; Ho H.J.; Yang H.-I.; Tseng T.-C.; Hosaka T.; Trinh H.N.; Kwak M.-S.; Park Y.M.; Fung J.Y.Y.; Buti M.; Rodr?guez M.; Treeprasertsuk S.; Preda C.M.; Ungtrakul T.; Charatcharoenwitthaya P.; Li X.; Li J.; Zhang J.; Le M.H.; Wei B.; Zou B.; Le A.; Jeong D.; Chien N.; Kam L.; Lee C.-C.; Riveiro-Barciela M.; Istratescu D.; Sriprayoon T.; Chong Y.; Tanwandee T.; Kobayashi M.; Suzuki F.; Yuen M.-F.; Lee H.-S.; JIA-HORNG KAO; Lok A.S.; Wu C.-Y.; Nguyen M.H.
臺大學術典藏 2021-09-04T05:16:53Z Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:53Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:53Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:52Z Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done Hsu Y.-C.; Tseng C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:52Z APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏 2021-09-04T05:16:52Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:52Z The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:51Z Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:51Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:51Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:50Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:50Z Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:50Z Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma Li Y.-T.; Wu H.-L.; JIA-HORNG KAO; Cheng H.-R.; Ho M.-C.; Wang C.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T05:16:49Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:49Z Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping JIA-HORNG KAO; Lin C.-Y.; Chuang W.-L.; Cheng Y.-Y.; Hu J.-Y.; Liang W.-K.; Friebe P.; Palmer S.; Huang C.-S.
臺大學術典藏 2021-09-04T05:16:49Z Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:48Z Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; Liu C.-H.; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏 2021-09-04T05:16:48Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:48Z Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:47Z APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Kadir Dokmeci A.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Ooka Y.; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏 2021-09-04T05:16:47Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:47Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:46Z NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging Su T.-H.; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:46Z Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:45Z Nucleos(t)ide analogues in patients with chronic hepatitis B: To stop or not to stop? JIA-HORNG KAO; Berg T.
臺大學術典藏 2021-09-04T05:16:45Z Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:45Z High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:44Z Systematic review: chronic viral hepatitis and metabolic derangement Wang C.-C.; Cheng P.-N.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:44Z Hepatobiliary and Pancreatic: Biliary hamartoma manifests as liver cysts Lin H.-H.; Liao S.-H.; Huang Y.-L.; Liu K.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:44Z Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? Hsu S.-J.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:44Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:43Z Letter: hepatitis B virus infection and risk of multiple myeloma—a meta-analysis of cohort studies. Authors' reply Su T.-H.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:43Z Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; Su T.-H.; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO; Yuen M.-F.; Yu M.-L.; Nguyen M.H.
臺大學術典藏 2021-09-04T05:16:42Z An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO; Hsu S.-J.; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L.

顯示項目 591-640 / 1180 (共24頁)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
每頁顯示[10|25|50]項目